Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

被引：13
|
作者：
Cohen, Ezra E. W.
Nabell, Lisle
Wong, Deborah J. L.
Day, Terry A.
Daniels, Gregory A.
Milhem, Mohammed M.
Deva, Sanjeev
Jameson, Michael B.
Guntinas-Lichius, Orlando
Almubarak, Mohammed
Strother, Robert Matthew
Whitman, Eric D.
Chisamore, Michael Jon
Obiozor, Cynthia Chinedu
Bagulho, Teresa
Candia, Albert
Gamelin, Erick
Janssen, Robert
Algazi, Alain Patrick
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[4] Med Univ South Carolina, Charleston, SC 29425 USA
[5] Univ Iowa, Iowa City, IA USA
[6] Auckland City Hosp, Auckland, New Zealand
[7] Waikato Hosp, Reg Canc Ctr, Hamilton, New Zealand
[8] Univ Hosp Jena, Head & Neck Surg, Jena, Germany
[9] West Virginia Univ, Morgantown, WV 26506 USA
[10] Christchurch Hosp, Canterbury Dist Hlth Board, Christchurch, New Zealand
[11] Atlantic Hlth Syst Canc Care, Morristown, NJ USA
[12] Merck & Co Inc, Rahway, NJ 07065 USA
[13] Dynavax Technol Corp, Berkeley, CA USA
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6039
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC)
    Cognetti, David M.
    Curry, Joseph M.
    Civantos, Francisco F.
    Valentino, Joseph
    Agbaje-Williams, Mayowa
    Danesi, Hassan
    Dong, Haiying
    Larracas, Cristina
    Veresh, Bogdan
    Gillenwater, Ann M.
    Su, Shirley Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Saada-Bouzid, E.
    Defaucheux, C.
    Karabajakian, A.
    Coloma, V. P.
    Servois, V.
    Paoletti, X.
    Even, C.
    Fayette, J.
    Guigay, J.
    Loirat, D.
    Peyrade, F.
    Alt, M.
    Gal, J.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1605 - 1611
  • [23] A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC
    Colevas, A. Dimitrios Dimitrios
    Dinis, Jose Prime
    Chin, Venessa T.
    Costa, Diogo Alpuim
    Park, John J.
    Fang, Bruno
    Phan, Minh Duc
    Zhang, Yiran
    U'Ren, Lance
    Odegard, Jared
    Curtis, Kelly Kevelin
    Pirtle, Erika
    Adkins, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma
    Villaret, D
    Glisson, B
    Kenady, D
    Hanna, E
    Carey, M
    Gleich, L
    Yoo, GH
    Futran, N
    Hung, MC
    Anklesaria, P
    Heald, AE
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (07): : 661 - 669
  • [25] Updated Dose Expansion Results of a Phase 1/1b Study of the Bifunctional EGFR/TGFβ Inhibitor BCA101 with Pembrolizumab in Patients with Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma
    Hanna, G. J.
    Kaczmar, J.
    Zandberg, D. P.
    Wong, D. J.
    Yilmaz, E.
    Sherman, E.
    Hernando-Calvo, A.
    Sacco, A.
    Raben, D.
    Odogwu, L.
    Bohr, D.
    Salazar, R.
    Reiners, R.
    Chung, C. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E88 - E88
  • [26] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck
    Taylor, Matthew H.
    Rasco, Drew W.
    Brose, Marcia S.
    Vogelzang, Nicholas J.
    Richey, Stephen L.
    Cohen, Allen L.
    Richards, Donald A.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Guo, Matthew
    Shumaker, Robert C.
    Schmidt, Emmett V.
    Young, Louise
    Wirth, Lori J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 174
  • [27] Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC).
    Chakravarthy, Karthik
    Kaczmar, John M.
    Riesenberg, Brian
    Britten, Carolyn D.
    Brisendine, Alan
    Hill, Elizabeth Goodwin
    Liu, Bei
    Li, Zihai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] A phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma (HNSCC)
    Yang, E. S.
    Deutsch, E.
    Mehmet, A.
    Fayette, J.
    Nabell, L.
    Spencer, S. A.
    Dobelbower, M. C.
    Willey, C. D.
    Bonner, J. A.
    Wang, X.
    Lin, A.
    William, W. N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1136 - 1136
  • [29] Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.
    Puram, Sidharth
    Oppelt, Peter John
    Ley, Jessica C.
    Cohen, Jared
    Alberti, Justin
    Shannon, Erik
    Liu, Jingxia
    Adkins, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Phase 2 Trial of AT-101 in Combination With Docetaxel for Recurrent, Locally Advanced, or Metastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC) Management of Recurrent Head-and-Neck Squamous Cell Carcinoma
    Sacco, A.
    Nor, J.
    Belile, E.
    Sukari, A.
    Chepeha, D.
    Bradford, C.
    Eisbruch, A.
    Wolf, G.
    Urba, S.
    Worden, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 507 - 507
12345